These insights provide a deeper understanding of the molecular mechanisms underlying β cell dysfunction in obesity and diabetes, emphasizing HNF4α as a potential therapeutic target for improving β cell resilience and function in metabolic diseases. This evidence concerns the gene HNF4A and diabetes mellitus.